EP 2026798 A1 20090225 - PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS
Title (en)
PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT CBX CANNABINOID-REZEPTOR-MODULATOREN UND KALIUMKANAL-MODULATOREN
Title (fr)
COMPOSITIONS PHARMACEUTIQUES CONTENANT DES MODULATEURS DE RÉCEPTEURS AUX CANNABINOÏDES CBX ET DES MODULATEURS DE CANAUX POTASSIUM
Publication
Application
Priority
- EP 2007053914 W 20070420
- EP 06113188 A 20060427
- EP 07728371 A 20070420
Abstract (en)
[origin: WO2007125048A1] The invention is directed to pharmaceutical compositions comprising pharmacologically effective quantities of each of a) at least one K<SUB>ATP</SUB> channel modulator as a first active agent and b) at least one CB<SUB>x </SUB>modulator as a second active agent. The invention further relates to the use of such compositions and to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans by administering such compositions to subjects in need thereof. The invention also is directed to processes of manufacturing such compositions.
IPC 8 full level
A61K 31/045 (2006.01); A61K 31/415 (2006.01); A61K 31/426 (2006.01); A61P 3/00 (2006.01); A61P 9/00 (2006.01)
CPC (source: EP KR)
A61K 31/045 (2013.01 - EP KR); A61K 31/415 (2013.01 - EP KR); A61K 31/426 (2013.01 - EP KR); A61P 3/00 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/08 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/04 (2017.12 - EP); A61P 9/06 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 9/12 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 13/02 (2017.12 - EP); A61P 15/10 (2017.12 - EP); A61P 17/14 (2017.12 - EP); A61P 19/06 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/08 (2017.12 - EP)
Citation (search report)
See references of WO 2007125048A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK RS
DOCDB simple family (publication)
WO 2007125048 A1 20071108; AR 060625 A1 20080702; AU 2007245733 A1 20071108; BR PI0711064 A2 20110823; CA 2650566 A1 20071108; CN 101431998 A 20090513; EA 200802132 A1 20090630; EP 2026798 A1 20090225; IL 194942 A0 20090803; JP 2009534439 A 20090924; KR 20090007606 A 20090119; MX 2008013678 A 20081104; TW 200808785 A 20080216
DOCDB simple family (application)
EP 2007053914 W 20070420; AR P070101747 A 20070423; AU 2007245733 A 20070420; BR PI0711064 A 20070420; CA 2650566 A 20070420; CN 200780015235 A 20070420; EA 200802132 A 20070420; EP 07728371 A 20070420; IL 19494208 A 20081027; JP 2009507042 A 20070420; KR 20087028616 A 20081121; MX 2008013678 A 20070420; TW 96114779 A 20070426